Vexim, the Specialist in Mini-Invasive Solutions for Treating Traumatic Spinal Pathologies Gets the 2012 NYSE Alternext Prize.

  Vexim, the Specialist in Mini-Invasive Solutions for Treating Traumatic
  Spinal Pathologies Gets the 2012 NYSE Alternext Prize.

Vexim was awarded the 2012 NYSE Alternext prize on Wednesday 5 December at the
 close of the 2^nd edition of the annual stock market conference that brought
         together several hundred members of the financial community

Business Wire

TOULOUSE, France -- December 06, 2012

Regulatory News :

Vexim (FR0011072602 ‐ ALVXM) (Paris:ALVXM), a medical device company
specialising in minimally invasive treatment of vertebral fractures, today
announces it has been awarded the NYSE Alternext Paris prize at the close of
NYSE Euronext’s 2^nd edition of the stock market annual conference (conférence
annuelle du marché boursier) on 5 December 2012. This award is in recognition
of Vexim’s successful IPO on NYSE Alternext in April 2012 and its good
performance since then.

“We are delighted to have been awarded the NYSE Alternext prize that ends a
pivotal year for the company. Vexim has been at the forefront for the last few
months thanks to our successful IPO, the strengthening of our Senior
Management and the setup of foreign subsidiaries.” stated Vincent Gardès, CEO
of Vexim. “I would like to thank all of our shareholders, especially Truffle
Capital for their support and trust, and I would personally like to express my
very special gratitude to Philippe Pouletty, co-founder and General Partner of
Truffle Capital, whose ongoing contribution helped us make this project a
success. Thanks to them, we can further our goal of establishing the
SpineJack® implant as the standard treatment of vertebral compression
fractures and to continue working on new innovative solutions in the spinal
field.”

In April 2012, Vexim successfully raised €11m when it carried out its IPO on
the NYSE Alternext in Paris.
The company has developed the SpineJack®; a mini-implant made out of titanium
with CE marking that makes it possible to restore the anatomy of the vertebra,
similar to that prior to the fracture following a minor percutaneous surgical
procedure of approximately 30 minutes.
The patient is sent home shortly after the operation following the recovery of
his or her functional abilities, thus regaining a better quality of life.

Vexim has always led a very active R&D policy with the support of their
longstanding shareholder, Truffle Capital that has been a key player in the
company’s growth with the preparation, launch and success of their IPO. Vexim
has a comprehensive range of SpineJack® implants enabling 95% of vertebral
compression fractures to be treated and is carrying on its research program to
create new solutions for other spinal pathologies.

Vexim is part of a worldwide marked estimated at over €850 million with
treatment of vertebral compression fractures on a steady progression of about
12% per year^1, carried out by a strong call for innovative solutions with the
addressable market reaching billions of euros. Vexim has its own sales team in
France, Germany, Italy and Switzerland as well as distributors in Spain,
Turkey, Argentina and South Africa.
The annual stock market conference was created to bring and connect together
the financial community; issuers, investors, financial intermediates and
advisors; dedicated to capital markets. This key annual event organized with
the involvement from executives of listed companies around round tables,
enables a first year evaluation and addresses their common challenges.

About Vexim, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), Vexim is a medical device specialist
created in February 2006 following its spinoff from Teknimed, a world leader
in bone substitutes and surgical cements. Vexim has specialised in the
creation and marketing of mini-invasive solutions for treating traumatic
spinal pathologies. Benefitting from the financial support of its longstanding
shareholders, Truffle Capital and Banexi Venture, and from OSEO public
subsidies, Vexim has designed and developed the SpineJack®, a unique implant
capable of repairing a deformed or fractured vertebra and correcting the
anatomy of the spinal column. The Company currently has 35 staff. It has its
own sales teams in France, Germany, Italy and Switzerland, as well as
distributors in Spain, Turkey, Argentina and South Africa. Vexim has been
listed on NYSE Alternext Paris since 3 May 2012.
For further information, please go to www.vexim.com

SpineJack®, a revolutionary implant for treating Vertebral Compression
Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a
fractured vertebra to its original shape, restore the spinal column’s optimal
anatomy and thus remove pain and enable the patient to recover their
functional capabilities. Thanks to a specialised range of instruments,
inserting the implants into the vertebra is carried out in a mini-invasive
manner, guided by X-ray, in approximately 30 minutes, enabling the patient to
be discharged shortly after surgery. The SpineJack® range consists of 3
titanium implants with 3 different diameters, thus covering 95% of vertebral
compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific
experts in the field of spinal columns, good medical-expense reimbursement
systems in Europe and worldwide patent protection through to 2029

^1 Source: iData Research

  *Libellé : Vexim
  *Code ISIN : FR0011072602
  *Mnémonique : ALVXM

Contact:

Vexim
Vincent Gardès
Directeur général
Tél. : 05 61 48 48 38
v.gardes@vexim.fr
or
NewCap.
Communication financière et Relations Investisseurs
Dusan Oresansky / Emmanuel Huynh
Tél. : 01 44 71 94 92
vexim@newcap.fr
or
Alize RP
Relations Presse
Caroline Carmagnol
Tél. : 06 64 18 99 59
caroline@alizerp.com
or
Christian Berg
Tel : 01 42 68 86 41
christian@alizerp.com
 
Press spacebar to pause and continue. Press esc to stop.